02.27.17
Johnson & Johnson posted a 1.7% rise in sales to $18.1 billion for the fourth quarter of 2016. J&J’s worldwide sales for the full-year 2016 increased 2.6% to $71.9 billion. Worldwide operational results, excluding the net impact of acquisitions and divestitures, were driven by over-the-counter products, including Listerine oral care products, Tylenol analgesics, digestive health products and anti-smoking aids; as well as Neutrogena and Aveeno beauty products.